Cysteamine-bicalutamide combination treatment restores alpha-ketoglutarate and corrects proximal tubule phenotype in cystinosis
Jamalpoor, A.; van Gelder, C. A.; Yousef Yengej, F. A.; Zaal, E. A.; Berlingerio, S. P.; Veys, K. R.; Pou Casellas, C.; Voskuil, K.; Essa, K.; Ammerlaan, C. M.; Rega, L. R.; van der Welle, R. E. N.; Lilien, M. R.; Rookmaaker, M. B.; Clevers, H.; Klumperman, J.; Levtchenko, E.; Berkers, C. R.; Verhaar, M. C.; Altelaar, M.; Masereeuw, R.; Janssen, M. J.
Show abstract
Nephropathic cystinosis is a severe monogenetic kidney disorder caused by mutations in CTNS, encoding the lysosomal transporter cystinosin, resulting in lysosomal cystine accumulation. The sole treatment, cysteamine, slows down the disease progression, but does not correct the established proximal tubulopathy. Here, we developed a new therapeutic strategy by applying an omics-based strategy to expand our knowledge on the complexity of the disease and prioritize drug targets in cystinosis. We identified alpha-ketoglutarate as a key metabolite linking cystinosin loss, lysosomal autophagy defect and proximal tubular impairment in cystinosis. This insight offered a bicalutamide-cysteamine combination treatment as a novel dual target pharmacological approach for the phenotypical correction of cystinotic proximal tubule cells, patient-derived kidney tubuloids and cystinotic zebrafish.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.